Case Study: Leading Pharma Company achieves optimal launch pricing for an orphan cardiovascular drug with Quantzig

Analyzing the Role of Pricing Analytics Techniques in Setting an Optimal Launch Price for an Orphan Cardiovascular Drug

Leading Pharma Company partnered with Quantzig to develop an optimal launch pricing strategy for its orphan cardiovascular drug in the US market. Facing stagnant healthcare budgets, limited pricing benchmarks for a rare disease treatment, and uncertainty around payer and physician response, the customer wanted to use pricing analytics to better understand the clinical and commercial factors that would shape adoption and profitability.

Quantzig implemented a three-phase pricing analytics engagement: internal and external stakeholder interviews, testing of price points and pricing structures to identify psychological thresholds, and development of a pricing roadmap aligned to business goals. As a result, the Leading Pharma Company was able to make strategic and tactical pricing decisions, prioritize three pricing analytics techniques for launch, and identify the optimal price to maximize revenue.